scholarly journals Efficient Generation of NKX6-1+ Pancreatic Progenitors from Multiple Human Pluripotent Stem Cell Lines

2015 ◽  
Vol 4 (4) ◽  
pp. 591-604 ◽  
Author(s):  
M. Cristina Nostro ◽  
Farida Sarangi ◽  
Chaoxing Yang ◽  
Andrew Holland ◽  
Andrew G. Elefanty ◽  
...  
Stem Cells ◽  
2011 ◽  
Vol 29 (7) ◽  
pp. 1158-1164 ◽  
Author(s):  
Niels-Bjarne Woods ◽  
Aaron S. Parker ◽  
Roksana Moraghebi ◽  
Margaret K. Lutz ◽  
Amy L. Firth ◽  
...  

2016 ◽  
Vol 16 (3) ◽  
pp. 735-739
Author(s):  
Federico González-Pozas ◽  
Rosa Montes ◽  
Lourdes López-Onieva ◽  
Tamara Romero ◽  
Joan Domingo-Reinés ◽  
...  

2015 ◽  
Vol 370 (1680) ◽  
pp. 20140365 ◽  
Author(s):  
Maria Rostovskaya ◽  
Nicholas Bredenkamp ◽  
Austin Smith

Human pluripotent stem cells can in principle be used as a source of any differentiated cell type for disease modelling, drug screening, toxicology testing or cell replacement therapy. Type I diabetes is considered a major target for stem cell applications due to the shortage of primary human beta cells. Several protocols have been reported for generating pancreatic progenitors by in vitro differentiation of human pluripotent stem cells. Here we first assessed one of these protocols on a panel of pluripotent stem cell lines for capacity to engender glucose sensitive insulin-producing cells after engraftment in immunocompromised mice. We observed variable outcomes with only one cell line showing a low level of glucose response. We, therefore, undertook a systematic comparison of different methods for inducing definitive endoderm and subsequently pancreatic differentiation. Of several protocols tested, we identified a combined approach that robustly generated pancreatic progenitors in vitro from both embryo-derived and induced pluripotent stem cells. These findings suggest that, although there are intrinsic differences in lineage specification propensity between pluripotent stem cell lines, optimal differentiation procedures may consistently direct a substantial fraction of cells into pancreatic specification.


2010 ◽  
Vol 18 (12) ◽  
pp. 2173-2181 ◽  
Author(s):  
Veronica Ramos-Mejia ◽  
Gustavo J Melen ◽  
Laura Sanchez ◽  
Ivan Gutierrez-Aranda ◽  
Gertrudis Ligero ◽  
...  

2012 ◽  
Vol 7 (5) ◽  
pp. 675-683 ◽  
Author(s):  
Jennifer L Badger ◽  
Meg L Byrne ◽  
Farlan S Veraitch ◽  
Chris Mason ◽  
Ivan B Wall ◽  
...  

2020 ◽  
Vol 44 ◽  
pp. 101721 ◽  
Author(s):  
Lydiane Pichard ◽  
Jean-Marc Brondelo ◽  
Fabienne Becker ◽  
Romain Desprat ◽  
Frédéric De Ceuninck ◽  
...  

Cells ◽  
2019 ◽  
Vol 8 (12) ◽  
pp. 1523 ◽  
Author(s):  
Laetitia Barrault ◽  
Jacqueline Gide ◽  
Tingting Qing ◽  
Lea Lesueur ◽  
Jorg Tost ◽  
...  

Substantial variations in differentiation properties have been reported among human pluripotent cell lines (hPSC), which could affect their utility and clinical safety. We characterized the variable osteogenic capacity observed between different human pluripotent stem cell lines. By focusing on the miRNA expression profile, we demonstrated that the osteogenic differentiation propensity of human pluripotent stem cell lines could be associated with the methylation status and the expression of miRNAs from the imprinted DLK1/DIO3 locus. More specifically, quantitative analysis of the expression of six different miRNAs of that locus prospectively identified human embryonic stem cells and human-induced pluripotent stem cells with differential osteogenic differentiation capacities. At the molecular and functional levels, we showed that these miRNAs modulated the expression of the activin receptor type 2B and the downstream signal transduction, which impacted osteogenesis. In conclusion, miRNAs of the imprinted DLK1/DIO3 locus appear to have both a predictive value and a functional impact in determining the osteogenic fate of human pluripotent stem cells.


Sign in / Sign up

Export Citation Format

Share Document